New Valeritas V-Go HEOR Data

Valeritas announced the publication of new HEOR data for its V-Go daily insulin patch pump for T2DM. The V-GoAL study was a randomized trial of 415 T2DM patients which resulted in 24% less total daily insulin as well as statistically significant reductions in A1C compared to standard treatment optimization. Below, FENIX provides thoughts on the V-Go system in the context of the emerging patch pump market.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.